ArticleMicrobial biotechnology2026
Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage-Driven Resistance.
Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Phage therapy is increasingly recognised as a potential approach against antibiotic-resistant infections. Analogous to the rise of antibiotic resistance, bacteria can also evolve phage resistance, a process that frequently entails fitness costs. In this study, a new lytic Pseudomonas aeruginosa phage (Henu5) was isolated and characterised. Henu5 was classified within the Caudoviricetes class and displayed good biological characteristics. The Henu5 genome possesses 92,558 bp of linear dsDNA and a GC content of 49.36%. Additionally, three phage-resistant mutants, R3, R6 and R14, were isolated and investigated for adaptive trade-offs. Compared to wild-type, the phage-resistant mutants mostly exhibited fitness costs in growth, altered morphology, impaired adsorption, reduced biofilm and pyocyanin production and impaired motility, which was confirmed by transmission electron microscopy, as well as increased susceptibility to various antibiotics. In vivo experiments revealed improved survival, alongside diminished colonisation and pathogenicity. Comparative genomics identified mutations in the genes pilQ (R3 and R14) and pilR (R6), both crucial for type IV pili (T4P) biosynthesis and potentially conferring phage resistance, with additional mutations related to the obtained trade-offs. Transcriptomic and real-time quantitative PCR proved that T4P-related genes, together with the hmgA, galU, wzy, fliG, pslA, mexH and exoY genes, were downregulated in all resistant mutants, while the qscR and mvaT genes were upregulated. Collectively, while phage resistance evolution remains an issue, this study suggests that the fitness costs of the phage-resistant mutants might be invaluable for effective phage therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.